<DOC>
	<DOCNO>NCT00213096</DOCNO>
	<brief_summary>The purpose 3-month ( cycle ) study evaluate effect hormonal contraceptive contain progestin estrogen liver proteins coagulation factor sensitive estrogen . In study , contraceptive vaginal ring contain Nestorone® ( progestin androgenic property ) ethinyl estradiol compare oral contraceptive contain levonorgestrel ( androgenic progestin ) ethinyl estradiol .</brief_summary>
	<brief_title>Effects Hormonal Contraceptives Liver Proteins Coagulation Factors : A Comparison Contraceptive Vaginal Ring Oral Contraceptive</brief_title>
	<detailed_description>The purpose 3-month ( cycle ) study evaluate effect hormonal contraceptive contain progestin estrogen liver proteins coagulation factor sensitive estrogen . In study , contraceptive vaginal ring contain Nestorone® ( progestin androgenic property ) ethinyl estradiol compare oral contraceptive contain levonorgestrel ( androgenic progestin ) ethinyl estradiol .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>ST 1435</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Healthy woman , age 1834 year , wish become pregnant 3 month ( 5 month first discontinue oral contraceptive Intact uterus least 1 ovary Have regular menstrual cycle ( 28 ± 7 day ) 2 regular cycle parturition abortion Willing use condom sexual intercourse 3 month study ( 5 month discontinue oral contraceptive ) , Willing continue use specify nonhormonal method birth control include permanent sterilization , nonhormonecontaining IUD , male condom , abstinence study use condom discontinue one method Willing able comply protocol Willing able sign inform consent prior entry study prior discontinue another method contraception Easy venous access Pregnancy Known hypersensitivity estrogens progestin Known hypersensitivity silicone rubber Undiagnosed vaginal discharge vaginal lesion abnormality Smoking status : &gt; 15 cigarette per day Breastfeeding Current past thrombophlebitis thromboembolic disorder Family history venous thrombosis embolism ( 1st degree relative &lt; 55 year age ) Known history Factor V Leiden positive screen test APCresistance Current past cerebrovascular coronary artery disease Carcinoma ( hormonedependent tumor ; past history carcinoma remission &gt; 5 year ) Medically diagnose severe depression Headaches focal neurological symptom Undiagnosed abnormal genital bleed History cholestatic jaundice pregnancy jaundice prior steroid use Benign malignant liver tumor ; active liver disease Diastolic/systolic BP ≥90/140 mmHg 5 min . rest Known suspected alcoholism ( &gt; 2 drinks/day ) drug abuse Positive hepatitis B &amp; C and/or HIV 1 2 , abnormal screening CBC , serum chemistry value ( include fasting , total cholesterol triglyceride ) , abnormal Pap smear , abnormal finding dipstick urinalysis , abnormal electrocardiogram ( ECG ) Participation clinical trial within last 3 month 1 trial last year BMI ( kg/m2 ) &gt; 28 Use injectable contraceptive last 6 month ( e.g . cyclofem DMPA ) Unwilling stop oral contraceptive 2 month prior study initiation Use implant hormonal contraceptive , include Mirena Implanon , last 2 year Not live catchment area clinic*Severe cystocele rectocele</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Contraceptive agent</keyword>
	<keyword>female</keyword>
</DOC>